

PARTICULATE MATTER

Cardiopulmonary Effects of Acute and Subchronic Exposure to Concentrated Ambient Particulates in Healthy and Compromised Rats

William P. Watkinson¹, Lindsay B. Wichers², Julianne P. Nolan¹, Janice A. Dye¹, Urmila P. Kodavanti¹, Kevin L. Dreher¹, Leon C. Walsh¹, Edwin R. Lappi¹, Darrell W. Winsett¹, James Lehmann¹, Dock Terrell¹, and Daniel L. Costa¹

1PTB; ²UNC SPH

METHODS

• Epidemiological studies have consistently demonstrated small but significant correlations between the levels of ambient particulate matter (PM) and the incidence of cardiopulmonary-related morbidity and mortality; these correlations appear to be strengthened when limited to persons with pre-existing cardiopulmonary disease

INTRODUCTION


- Numerous animal studies have been conducted to elucidate these issues, however, most have employed high concentrations of fairly toxic particles
- Relatively little is known regarding the effects of lower concentrations of more "environmentally-relevant" PM
- The goal of these studies was to examine the cardiac, pulmonary, and thermoregulatory effects of Concentrated Ambient Particulates (CAPs) in a number of rodent models of cardiopulmonary disease





 Experimental Conditions: animals: Spontaneously Hypertensive, Fischer-344 or Sprague-Dawley rats n=16-24/study; 4-12 rats/group experimental treatment: CAPs exposure regimens: 1) 2-3 day/wk × 11 wk 2) 1 day/wk × 11 wk 3) 2-3 day/wk × 2 wk 4) 2-3 day/wk × 1 wk exposure: nose-only inhalation sacrifice: 24 hours post-exposure 	 Endpoints Assessed: heart rate, blood pressure, core temperature, QA interval activity body weight heart and lung weights ECG intervals/durations arrhythmias pulmonary function BALF constituents serum enzymes heart and lung histopathology 		
Procedure: • implant radiotelemeters • recovery period (10 d) • control period (3 d) • nose-only exposure • monitor cardiopulmonary endpoints	Stage 3 Stage 2 Stage 1 (5 sits) Cudstor AP 3750 Lpm 2 5 pm sac executive solid Exposure Chamber Stage 1 (5 sits) Chamber Stage 1 (5 sits) Chamber Stage 1 (5 sits) Cudstor AP 3750 Lpm 2 pm sac 3 pm sac		


Concentrated Ambient Particulate Studies					
INVESTIGATOR	YEAR	ANIMAL STRAIN/ DISEASE MODEL	EXPOSURE DURATION	PRIMARY ENDPOINTS	MOST IMPORTANT FINDING
Kodavanti	1997	Rat; SD bronchitis	2 d×5 reps	pulmonary inflammation pulmonary injury	↑ inflammation (3 of 5) ↑ BALF protein
Gavett	1998	Mouse; Balb/cJ, Wild Type, Mast Cell Deficient allergic asthma	2 d×3 reps	airway responsiveness pulmonary inflammation	WT: ↑ BALF eosinophils MCD: small ↑ BALF eosinophils
Gilmour	1999	Rat; SD healthy	3 d/wk×5 wk	pulmonary inflammation pulmonary injury	↑ BALF macrophages, neutrophils ↑ fibrinogen
Gilmour	1999	Mouse; CD1, C3H healthy	3 d×6 reps	pulmonary inflammation pulmonary bacteria	sporadic ↑ infectivity
Kodavanti	2000	Rat; SH systemic hypertension	2 d/wk×1 wk 2 d/wk×9 wks	BALF/blood biomarkers antioxidants	small ↑ fibrinogen
Kodavanti	2000	Rat; SH systemic hypertension	1 d×6 reps	cardiopulmonary function BALF/blood biomarkers	small ↑ fibrinogen
Dye	2001	Rat; SH, WKY Aged	2 d×1 rep	BALF/blood biomarkers antioxidants	age-related effects no CAPs potentiation of effects
Kodavanti	2001	Rat; SH, WKY systemic hypertension	2 d×9 reps	BALF/blood biomarkers antioxidants	WKY: ↑ neutrophils, ↓ total cells SH: ↑ fibrinogen, ↓ GGT
Costa	2002	Rat; SH systemic hypertension	1 d/wk×11 wks	cardiopulmonary function BALF/blood biomarkers	in progress
Dreher	2002	Rat; SD healthy	2–3 d/wk×11 wks	cardiac function	in progress
Dye	2002	Rat; SD antioxidant depleted	2 d×2 reps	BALF/blood biomarkers antioxidants cell proliferation	small ↑ neutrophils
Kodavanti	2002	Rat; WKY antioxidant depleted	2 d×2 reps	BALF/blood biomarkers antioxidant cell proliferation	small ↑ neutrophils
Rogers	2002	Rat; F-344 pregnant	3 d/wk×2 wks× 2 reps	maternal/fetal weight fetal morphology	in progress
Watkinson	2002	Rat; SH systemic hypertension	2-3 d×9 wks	cardiopulmonary function BAL/blood biomarkers	in progress
Watkinson	2002	Rat; SH systemic hypertension, aged	3 d/wk×1 wk	cardiopulmonary function BAL/blood biomarkers	in progress
Watkinson	2002	Rat; SD pulmonary hypertension	3 d/wk×1 wk	cardiopulmonary function BAL/blood biomarkers	in progress

SUBCHRONIC RESULTS











ACUTE RESULTS



Changes in Minute Ventilation and Penh in a Rodent Model of Cardiopulmonary Disease Following Exposure to CAPs

Effects of nose-only inhalation exposure to RTP CAPs on (a) minute ventilation and (b) penh of awake, adult Sprague-Dawley rats (n=24 rats, 6 rats/group). A subset of rats was injected with monocrotaline and allowed to recover for 14 days prior to CAPs exposure. Respiratory parameters were monitored using a whole-body plethysmographic system (Buxco Electronics for 10 min/d for 5 days. Data shown were collected one day prior to the first CAPs exposure (Control) and continued for one day post-exposure (Recovery); CAPs exposures occurred or September 10-12, 2002. The black line on Figure a represents the CAPs concentration in the exposure chamber for animals on that day (as shown on the right y-axis). Individual anima data were obtained at 10-s intervals but have been averaged over a 10-min period. Data in the figures are presented as group means ± SE; no values were found to be significantly different in either figure.



CONCLUSIONS AND IMPACT

- These studies underscore the inherent complexities of conducting discrete, limited toxicology studies using environmentally-relevant exposure protocols in order to verify large scale epidemiological studies
- Furthermore, these studies emphasize the importance of companion source characterization/apportionment studies to the overall PM research effort
- Determination of small, consistent changes in cardiopulmonary functional parameters in compromised rodents may help identify specific biologically-plausible mechanism/s responsible for the adverse effects observed in epidemiological studies.

FUTURE DIRECTIONS

- To further investigate the effects and mechanisms of PM-induced toxicity using environmentally-relevant exposure scenarios, we propose to develop, characterize, and test new animal models of susceptibility and/or cardiopulmonary disease.
- These animals will be exposed to RTP CAPs and subjected to the full battery of experimental procedures available in our laboratories. Particular emphasis will be placed on developing and improving specific cardiovascular methodologies, such as electrocardiographic interval and heart rate variability analyses, for application to rodent models, as well as improved statistical techniques to better identify subtle differences in functional endpoints.

SOLVING AGENCY PROBLEMS